Navigation Links
Experimental Drug Eases Symptoms of Mild Alzheimer's
Date:4/30/2008

Tarenflurbil lessened decline in functional ability, British study concludes

WEDNESDAY, April 30 (HealthDay News) -- Patients with mild Alzheimer's disease who took 800 milligrams of the drug tarenflurbil twice a day had less decline in functional ability than those who took a placebo, according to a British phase II trial.

The findings support phase III studies of the drug at this dose, the researchers said. Tarenflurbil reduces production of 42-amino-acid peptide, which is believed to initiate brain damage characteristic of Alzheimer's disease. Previous research had found the drug prevented learning and memory defects in mice with Alzheimer's disease.

In this study, 210 patients were randomly assigned to receive either 400 milligrams of tarenflurbil twice per day (69 patients), 800 milligrams of tarenflurbil twice per day (70 patients), or a placebo (71 patients).

Patients with mild Alzheimer's who took 800 milligrams of tarenflurbil for 24 months had lower rates of decline than those who were in the placebo group for the first 12 months of the study and either tarenflurbil group for the last 12 months of the study.

Common side effects included diarrhea, nausea and dizziness.

The researchers concluded that "800 mg tarenflurbil twice per day was well-tolerated for up to 24 months of treatment, with evidence of a dose-related effect on measures of daily activities and global function in patients with mild AD ... these findings justify phase III studies of tarenfurbil at the 800 mg twice daily dose in patients with mild AD."

The study was published online in The Lancet Neurology.

The findings are sufficient to support Phase III studies of the drug, Dr. Paul Aisen of the University of California, San Diego, wrote in an accompanying commentary.

"With the need so enormous, and the potential effect of the benefit suggested [although not proven] by these phase II results, the effort is indeed justified despite the substantial uncertainty. In a few months, we will learn whether tarenflurbil will be the first anti-amyloid intervention to be efficacious in a pivotal trial," Aisen wrote.

More information

The U.S. National Institute on Aging has more about Alzheimer's disease.



-- Robert Preidt



SOURCE: The Lancet, news release, April 29, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental Blood Substitutes Unsafe, Study Finds
2. Honda to Showcase Experimental Walking Assist Device
3. Experimental Alzheimers Drug Shows Promise
4. Experimental drug shows promise in treating certain lymphomas
5. Experimental Cancer Vaccines Show Promise
6. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
7. Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints
8. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
9. 52 minority scientists receive travel fellowships to Experimental Biology 2008
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. Experimental Vaccine Halts Prostate Cancer in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... ... “Call Of Spiritual Duty”: a revelation in an era defined by intentional ... Growing up on the streets of North Visalia, California, Carlos Lizarde quickly became familiar ... keys to his life, he noticed immediately that opportunities and blessings began to shift ...
(Date:8/21/2017)... ... August 22, 2017 , ... Nanoparticle research provides an exciting ... By learning and implementing best practices for containment using ventilated safety enclosures, many ... gain a better understanding of a method for safely testing nanotechnology hoods. They ...
(Date:8/21/2017)... ... August 21, 2017 , ... FCPX LUT Monochromatic Volume 2 is ... and easily add washed color grades to footage. A LUT is a Lookup Table ... color to the corresponding color indicated by the table. This pack comes with 60 ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... place all over the country. , Outdoor running increases exposure to ultraviolet radiation, ... an increased risk of melanoma, and only half may be adequately protecting themselves ...
(Date:8/21/2017)... New York, NY (PRWEB) , ... August 21, 2017 , ... ... healthcare brands, was recently named one of the Top 100 agencies of the year ... list in MM&M’s annual agency issue, marking an important milestone for the agency. ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... GAITHERSBURG, Md. , Aug. 7, 2017 /PRNewswire/ ... for healthcare member acquisition, retention, and engagement, announced ... Director of Strategy and Product Development, effective as ... strategic consulting and technology implementation strategy for our ... years of experience in consulting and business analytics ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/2/2017)... 2, 2017  Life Flight Network and PeaceHealth Oregon Network ... patient care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, ... and Life Flight Network work collaboratively to move patients who ... when a time sensitive emergency exists. ...
Breaking Medicine Technology: